Posted on 7/18/17
Johnson &Amp; Johnson Beats By $0.03, Misses On Revenue
Johnson & Johnson (NYSE:JNJ): Q2 EPS of $1.83 beats by $0.03.Revenue of $18.84B (+1.9% Y/Y) misses by $110M.Shares +1.01% PM.READ FULL ARTICLE HERE
Posted on 7/18/17
Johnson & Johnson: Approval Of TREMFYA Is Huge Win For Shareholders
Recently, the FDA approved Johnson & Johnson's (JNJ) treatment TREMFYA for patients with plaque psoriasis. That means Novartis (NVS), Eli Lilly (LLY), and Valeant Pharmaceuticals (VRX) . . .
Posted on 7/18/17
GE Healthcare and Jefferson Health Launch Multi-Year Risk-Sharing Relationship
PHILADELPHIA--(BUSINESS WIRE)--GE Healthcare and Jefferson Health have announced an eight-year, shared-risk relationship that will help Jefferson strategically transform healthcare delivery in the Philadelphia region for the . . .
Posted on 7/18/17
Pharmacy Times Ranks No. 1 Among Pharmacists in Average Page Exposures
CRANBURY, N.J.--(BUSINESS WIRE)--Pharmacy Times®, the leading media resource for pharmacists and the pharmacy industry, ranked the highest in ad visibility among pharmacy journals for Average Page . . .
Posted on 7/17/17
Strongbridge Biopharma Secures $53 Million Financing From CRG
Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases
Posted on 7/17/17
Previewing Johnson & Johnson Earnings
Ad creditJohnson & Johnson (JNJ) is a stock that I’ve moved around a bit on in the past few years. I’ve been pretty vehemently bearish at . . .
Posted on 7/17/17
Better Buy: Biogen Inc. vs. Celgene Corporation
Biogen (NASDAQ:BIIB) and Celgene (NASDAQ:CELG) have ranked among the most successful biotech stocks of the past decade. Biogen stock has soared more than 430% in the . . .
Posted on 7/17/17
Pfizer Is Set to Lose Its No. 1 Spot Among Drugmakers: Here's Why It Doesn't Matter
Pfizer (NYSE:PFE) stands at the top of the mountain when it comes to prescription drug sales. Last year, the big pharma company made $45.9 billion from . . .
Posted on 7/14/17
Pfizer Announces NDA Filing Acceptance By FDA For XELJANZ
Today, Pfizer (PFE) announced that its supplemental new drug application -- sNDA -- has been accepted for review by the FDA. The review will be on . . .
Posted on 7/14/17
Johnson & Johnson Looks for Second-Quarter Strength to Keep Upward Momentum
Healthcare conglomerate Johnson & Johnson (NYSE:JNJ) has been immensely successful over the years, and it has also done well for shareholders recently. With a nearly 15% . . .
Posted on 7/14/17
Merck's Constant Struggle With Leverage
Photo creditMerck (MRK), like its competitors in the mega-cap pharma space, has always valued capital returns. In this sector, dividends and buybacks are everything to shareholders, . . .
Posted on 7/13/17
Will Pfizer Keep Growing Its Dividend?
Pfizer (NYSE:PFE) is one of the largest pharmaceutical companies in the business, and millions of patients have benefited from its medications over the years. From top-selling . . .
Posted on 7/12/17
Why Celgene Corporation Stock Bolted Higher in June
What happenedAccording to S&P Global Market Intelligence, shares of the top biotech company Celegene Corp. (NASDAQ:CELG) rose by a healthy 11.56% last month. The drugmaker's shares . . .
Posted on 7/11/17
AmerisourceBergen Recognized as “Best In Class” for Specialty Distribution Quality
VALLEY FORGE, Pa.--(BUSINESS WIRE)--AmerisourceBergen, a global healthcare solutions leader, announced today that its third party logistics (3PL) provider, ICS, has become the first and only pharmaceutical . . .
Posted on 7/11/17
Should You Fear Talcum Litigation?
The company is being sued by about 1,500 plaintiffs.The science is not settled, some studies do find a connection to cancer cases, some do not.Johnson & . . .
Posted on 7/10/17
Better Buy: Amgen Inc. vs. Celgene Corporation
Biotechs don't get to be big biotechs without racking up major successes along the way. That's certainly the case for two of the biggest biotechs around . . .
Posted on 7/10/17
Here's Why Johnson & Johnson Is Valued at Its Highest P/E in a Decade
Healthcare conglomerate Johnson & Johnson (NYSE:JNJ) is what you might refer to as a "mainstay investment" for a lot of people. It's the largest publicly traded . . .
Posted on 7/10/17
Will Johnson & Johnson's Dividend Keep Climbing?
Johnson & Johnson (NYSE:JNJ) is a household name in healthcare, with popular consumer products like Band-Aid bandages and Tylenol over-the-counter pain-relief medicine. What many people don't . . .
Posted on 7/7/17
Johnson & Johnson: Where's The Growth Coming From?
Image creditJohnson & Johnson (JNJ) has long been a company that has many cash demands. It pays a sizable dividend, buys back stock by the billion . . .
Posted on 7/7/17
Pfizer: Is It Really That Bad?
A lot of investors seem to be quite pessimistic about Pfizer’s (PFE) future. The loss of exclusivity of certain important brands that are coming up are . . .
Posted on 7/7/17
Celgene Endorsement Sees Beigene Come Of Age
Beigene (NASDAQ:BGNE), a group that has had a consistent if low-key presence at recent oncology conferences, looks finally to have come of age. In licensing its . . .
Posted on 7/7/17
Merck: Good Long-Term Despite Major Setback
On Wednesday, Merck (MRK) was notified by the FDA that it was hit with a clinical hold on three multiple myeloma studies that were treating patients . . .
Posted on 7/7/17
A Botched Merger Sent Rite Aid's Shares Reeling 16% In June
What happenedAfter Walgreens Boots Alliance (NASDAQ:WBA) threw in the towel on plans to acquire Rite Aid (NYSE:RAD), Rite Aid's shares tumbled 16.4% to end June, according . . .
Posted on 7/7/17
Warren Buffett Is About to Buy Another Massive Utility -- Here's Why
According to reports, Berkshire Hathaway (NYSE:BRK-A) (NYSE:BRK-B) is close to finalizing a deal to purchase Texas-based utility Oncor, one of the largest electric utility companies in . . .
Posted on 7/7/17
Egalet Prices Public Offering of Common Stock and Warrants
Egalet Corporation (Nasdaq: EGLT), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, today announced the . . .

